155 related articles for article (PubMed ID: 17189071)
1. Using economic analysis to evaluate the potential of multimodality therapy for elderly patients with locally advanced pancreatic cancer.
Krzyzanowska MK; Earle CC; Kuntz KM; Weeks JC
Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):211-8. PubMed ID: 17189071
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Stainthorpe A; Greenhalgh J; Bagust A; Richardson M; Boland A; Beale S; Duarte R; Kotas E; Banks L; Palmer D
Pharmacoeconomics; 2018 Oct; 36(10):1153-1163. PubMed ID: 29600384
[TBL] [Abstract][Full Text] [Related]
3. Economic Evaluation for USA of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer.
Gharaibeh M; McBride A; Alberts DS; Slack M; Erstad B; Alsaid N; Bootman JL; Abraham I
Pharmacoeconomics; 2018 Oct; 36(10):1273-1284. PubMed ID: 29948964
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer.
Gharaibeh M; McBride A; Bootman JL; Patel H; Abraham I
J Med Econ; 2017 Apr; 20(4):345-352. PubMed ID: 27919186
[TBL] [Abstract][Full Text] [Related]
5. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.
Pandor A; Eggington S; Paisley S; Tappenden P; Sutcliffe P
Health Technol Assess; 2006 Nov; 10(41):iii-iv, xi-xiv, 1-185. PubMed ID: 17049138
[TBL] [Abstract][Full Text] [Related]
6. Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study.
Li CP; Chao Y; Chi KH; Chan WK; Teng HC; Lee RC; Chang FY; Lee SD; Yen SH
Int J Radiat Oncol Biol Phys; 2003 Sep; 57(1):98-104. PubMed ID: 12909221
[TBL] [Abstract][Full Text] [Related]
7. Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer.
Gharaibeh M; McBride A; Bootman JL; Abraham I
Br J Cancer; 2015 Apr; 112(8):1301-5. PubMed ID: 25791875
[TBL] [Abstract][Full Text] [Related]
8. Hypofractionated Conformal Radiotherapy with Concurrent Full-Dose Gemcitabine Versus Standard Fractionation Radiotherapy with Concurrent Fluorouracil for Unresectable Pancreatic Cancer: a Multi-Institution Experience.
Rakhra S; Strauss JB; Robertson J; McGinn CJ; Kim T; Huang J; Blake A; Helenowski I; Hayes JP; Mulcahy M; Small W
J Gastrointest Cancer; 2016 Jun; 47(2):196-201. PubMed ID: 27112332
[TBL] [Abstract][Full Text] [Related]
9. The clinical effectiveness and cost-effectiveness of gemcitabine for metastatic breast cancer: a systematic review and economic evaluation.
Takeda AL; Jones J; Loveman E; Tan SC; Clegg AJ
Health Technol Assess; 2007 May; 11(19):iii, ix-xi, 1-62. PubMed ID: 17462169
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of modern radiotherapy techniques in locally advanced pancreatic cancer.
Murphy JD; Chang DT; Abelson J; Daly ME; Yeung HN; Nelson LM; Koong AC
Cancer; 2012 Feb; 118(4):1119-29. PubMed ID: 21773972
[TBL] [Abstract][Full Text] [Related]
11. Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer.
Gharaibeh M; McBride A; Alberts DS; Erstad B; Slack M; Alsaid N; Bootman JL; Abraham I
Pharmacoeconomics; 2018 Nov; 36(11):1333-1343. PubMed ID: 29981004
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of treatments for metastatic pancreatic cancer based on PRODIGE and MPACT trials.
Zhou J; Zhao R; Wen F; Zhang P; Wu Y; Tang R; Chen H; Zhang J; Li Q
Tumori; 2016 Jun; 2016(3):294-300. PubMed ID: 27056335
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine chemotherapy versus 5-fluorouracil-based concurrent chemoradiotherapy in locally advanced unresectable pancreatic cancer.
Park JK; Ryu JK; Lee JK; Yoon WJ; Lee SH; Kim YT; Yoon YB
Pancreas; 2006 Nov; 33(4):397-402. PubMed ID: 17079946
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: a meta-analysis.
Zhu CP; Shi J; Chen YX; Xie WF; Lin Y
Radiother Oncol; 2011 May; 99(2):108-13. PubMed ID: 21571383
[TBL] [Abstract][Full Text] [Related]
15. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
Regine WF; Winter KA; Abrams RA; Safran H; Hoffman JP; Konski A; Benson AB; Macdonald JS; Kudrimoti MR; Fromm ML; Haddock MG; Schaefer P; Willett CG; Rich TA
JAMA; 2008 Mar; 299(9):1019-26. PubMed ID: 18319412
[TBL] [Abstract][Full Text] [Related]
16. Comparison of 5-FU and leucovorin to gemcitabine in the treatment of pancreatic cancer.
Klein B; Sadikov E; Mishaeli M; Levin I; Figer A
Oncol Rep; 2000; 7(4):875-7. PubMed ID: 10854561
[TBL] [Abstract][Full Text] [Related]
17. Survival after chemoradiation in resected pancreatic cancer: the impact of adjuvant gemcitabine.
Baschnagel A; Shah C; Margolis J; Nadeau L; Stein J; Jury R; Robertson JM
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e331-5. PubMed ID: 22420967
[TBL] [Abstract][Full Text] [Related]
18. Long-term results of full-dose gemcitabine with radiation therapy compared to 5-fluorouracil with radiation therapy for locally advanced pancreas cancer.
Huang J; Robertson JM; Margolis J; Balaraman S; Gustafson G; Khilanani P; Nadeau L; Jury R; McIntosh B
Radiother Oncol; 2011 May; 99(2):114-9. PubMed ID: 21621866
[TBL] [Abstract][Full Text] [Related]
19. In response to Li et al.: Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. IJROBP 2003;57:98-104.
Crane CH
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):1009; author reply 1009-10. PubMed ID: 14967465
[No Abstract] [Full Text] [Related]
20. Cost-effectiveness analysis of capecitabine compared with bolus 5-fluorouracil/l-leucovorin for the adjuvant treatment of colon cancer in Japan.
Shiroiwa T; Fukuda T; Shimozuma K; Ohashi Y; Tsutani K
Pharmacoeconomics; 2009; 27(7):597-608. PubMed ID: 19663530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
